Saturday, 31 October 2026European Markets

IMMOBEL, BASSAC, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Real Estate—Development Industry.

Loading stream...

(vianews) - immobel (immo.br) is among this list of stock assets with the highest dividend rate and return on equity on the real estate—development industry.

financial asset price forward dividend yield return on equity
immobel (immo.br) €39.70 7.66% 1.79%
bassac (bass.pa) €48.50 5.1% 14.33%
ctp (ctpnv.as) €12.16 3.87% 18.91%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. immobel (immo.br)

7.66% forward dividend yield and 1.79% return on equity

immobel sa engages in the real estate development business in belgium, luxemburg, france, germany, poland, and spain. the company undertakes office, residential, and retail projects, as well as develops real estate projects for living, working, and recreational activities. it also provides project management and leasing services. the company was formerly known as allfin nv and changed its name to immobel sa in june 2016. the company was incorporated in 1863 and is headquartered in brussels, belgium.

earnings per share

as for profitability, immobel has a trailing twelve months eps of €1.07.

pe ratio

immobel has a trailing twelve months price to earnings ratio of 37.1. meaning, the purchaser of the share is investing €37.1 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.79%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, immobel's stock is considered to be overbought (>=80).

volume

today's last reported volume for immobel is 1260 which is 58.79% below its average volume of 3058.

sales growth

immobel's sales growth for the current quarter is 120.2%.

volatility

immobel's last week, last month's, and last quarter's current intraday variation average was a negative 0.84%, a negative 0.53%, and a positive 1.98%.

immobel's highest amplitude of average volatility was 2.01% (last week), 1.63% (last month), and 1.98% (last quarter).

more news about immobel.

2. bassac (bass.pa)

5.1% forward dividend yield and 14.33% return on equity

bassac société anonyme operates as a real estate development company primarily in france, germany, and spain. it offers residential houses and apartments, as well as prefabricated garages and land. the company was incorporated in 1972 and is headquartered in boulogne-billancourt, france. as of december 31, 2021, bassac société anonyme operates as a subsidiary of premier investissement sas.

earnings per share

as for profitability, bassac has a trailing twelve months eps of €9.59.

pe ratio

bassac has a trailing twelve months price to earnings ratio of 5.06. meaning, the purchaser of the share is investing €5.06 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.33%.

yearly top and bottom value

bassac's stock is valued at €48.50 at 17:40 est, way below its 52-week high of €65.80 and above its 52-week low of €47.20.

moving average

bassac's value is under its 50-day moving average of €50.24 and below its 200-day moving average of €52.14.

sales growth

bassac's sales growth for the current quarter is negative 15.1%.

more news about bassac.

3. ctp (ctpnv.as)

3.87% forward dividend yield and 18.91% return on equity

ctp n.v. owns, develops, manages, and leases logistics and industrial real estate properties in central, western, and eastern europe. the company offers various building for small and growing businesses, global enterprises, built to suit, and other offices. it also develops urban parks which are harbour mixed-use building and space types, such as premium offices, retail stores, office services, public spaces, and other amenities. ctp n.v. was founded in 1998 and is based in amsterdam, the netherlands. ctp n.v. is a subsidiary of ctp holding b.v.

earnings per share

as for profitability, ctp has a trailing twelve months eps of €2.14.

pe ratio

ctp has a trailing twelve months price to earnings ratio of 5.68. meaning, the purchaser of the share is investing €5.68 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.91%.

volatility

ctp's last week, last month's, and last quarter's current intraday variation average was 0.39%, 0.17%, and 1.53%.

ctp's highest amplitude of average volatility was 2.12% (last week), 1.46% (last month), and 1.53% (last quarter).

moving average

ctp's worth is above its 50-day moving average of €11.94 and above its 200-day moving average of €11.88.

more news about ctp.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com